The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Assessing the increased diagnoses of early onset colorectal cancer
Elisa Fontana, MD, PhD, Sarah Cannon Research Institute, London, UK, discusses the growing concerns over the rise in early-onset colorectal malignancies and other gastrointestinal cancers, including pancreatic tumors. There is an emphasis on the need for more research into the epigenetic factors influencing colorectal cancer. Patients are now being identified based on genomic and germline mutations, with a focus on managing long-term toxicity and fertility issues that may arise in this population. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
